Mainz Biomed (MYNZ) CFO details stock option grants and vesting
Rhea-AI Filing Summary
Mainz Biomed N.V. Chief Financial Officer William J. Caragol filed an initial ownership report as of 01/01/2026. He reports beneficial ownership of 0 Ordinary Shares directly.
The filing lists several employee stock options to buy Ordinary Shares held directly. These include an option for 70,000 shares at an exercise price of $4.95, with 50% vested on 03/04/2025 and the remainder vesting 25% on 03/24/2026 and 25% on 03/04/2027. Additional options cover 3,899 shares at $200 (fully vested), 2,000 shares at $497.6, 1,000 shares at $302.8, and 1,000 shares at $191.2, each with four-year vesting schedules as described in the footnotes.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
Caragol William J
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 77,899 shares (Direct);
Ordinary Shares — 0 shares (Direct)
Footnotes (5)
- F1. 50% of the option vested upon grant on 03/04/2025; the remaining balance vests 25% on 03/24/26 and 25% on 03/04/2027.
- F2. Fully vested.
- F3. Four-year vesting schedule: 25% vests on 04/29/2023, and the remainder vests 1/36 per month until 4/29/2026.
- F4. Four-year vesting schedule: 25% vests on 12/21/2023, and the remainder vests 1/36 per month until 12/21/2026.
- F5. Four-year vesting schedule: 25% vests on 06/30/2024, and the remainder vests 1/36 per month until 6/30/2076.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the Form 3 filed for MYNZ disclose about insider ownership?
The Form 3 shows that Chief Financial Officer William J. Caragol directly owns 0 Ordinary Shares of Mainz Biomed N.V. as of 01/01/2026, but holds several employee stock options for Ordinary Shares.
Which Mainz Biomed (MYNZ) stock options are already fully vested for the CFO?
The option covering 3,899 Ordinary Shares at an exercise price of $200, granted on 11/04/2021, is described as fully vested.
How do the four-year vesting schedules work for the MYNZ CFO’s other options?
For the options granted on 04/29/2022, 12/21/2022, and 06/30/2023, 25% vests on the one-year anniversary of each grant date and the remainder vests at 1/36 per month until the respective end dates stated in the footnotes.
Does the MYNZ CFO hold his Mainz Biomed securities directly or indirectly?
The Form 3 shows all listed Ordinary Shares and employee stock options as held with direct ownership, with no indirect ownership entities disclosed in the excerpt.